|
|
Blood, 15 February 2004, Vol. 103, No. 4, pp. 1222-1228.
Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-04-1124.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
Marc André,
Nicolas Mounier,
Xavier Leleu,
Anne Sonet,
Pauline Brice,
Michel Henry-Amar,
Hervé Tilly,
Bertrand Coiffier,
André Bosly,
Pierre Morel,
Corinne Haioun,
Philippe Gaulard,
Felix Reyes,
Christian Gisselbrecht, and
the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
From the Hematology Department, Centre Hospitalier Notre Dame et reine Fabiola, Charleroi; Hematology Department, Cliniques Universitaires Mont Godinne, Yvoir, Belgium; Hematology Department, Hôpital Saint-Louis, Paris; Hematology Department, Centre Hospitalier Universitaire de Lille; Clinical Research Unit and INSERM CJF 96-03/Grecan, Centre Régional François Baclesse, Caen; Hematology Department, Centre Henri Becquerel, Rouen; Hematology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite; Hematology Department, Centre Hospitalier de Lens; and Hematology and Pathology Department, Hôpital Henri Mondor, Créteil, France.
The survival of patients with aggressive non-Hodgkin lymphoma (NHL) is increasing, but the incidence of secondary cancer and late toxicity is poorly defined for those treated with cyclophosphamide-hydroxydaunomycin/doxorubicin-Oncovin-prednisone (CHOP)–like chemotherapy. From February 1984 to January 1998, 2837 patients with aggressive NHL received the control-arm chemotherapy adriamycin-cyclophosphamide-vindesine-bleomycin-prednisone (ACVBP) in 3 consecutive Groupe d'Etude des Lymphomes de l'Adulte (GELA) studies. With a median follow-up time of 74 months, the 5-year overall and event-free survival rates were 60% and 52%. Two hundred two occurrences of nonneoplastic late toxicity were reported, resulting in a 5.35% cumulative probability of incidence at 7 years. Eighty-one second tumors developed, for which the 7-year cumulative incidence rate was 2.75%; 64 were solid tumors, and 17 were hematologic malignancies. In multivariate analysis, age was the only risk factor for the second development of cancer. Epidemiologic analysis allowed a comparison of this NHL group with the general population. Considering all tumors, no excess of second cancer was observed. In the male population, however, there was an excess of lung cancer (standardized incidence ratio [SIR], 2.45; P < .001) and myelodysplastic syndrome/acute myelocytic leukemia (MDS/AML) (SIR, 5.65; P = .006), and in the female population there was an excess of MDS/AML (SIR, 19.9; P < .001). With a long follow-up, the ACVBP regimen was highly effective for the treatment of aggressive NHL. Increases occurred in secondary MDS/AML and in lung cancer among men.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Green, M. Johnston, M. Trudeau, L. Schwartz, S. Poirier, G. Macartney, and D. Milliken
Safe Handling of Parenteral Cytotoxics: Recommendations for Ontario
J. Oncol. Pract,
September 1, 2009;
5(5):
245 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Leleu, J. Soumerai, A. Roccaro, E. Hatjiharissi, Z. R. Hunter, R. Manning, B. T. Ciccarelli, A. Sacco, L. Ioakimidis, S. Adamia, et al.
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom Macroglobulinemia Treated With Nucleoside Analogs
J. Clin. Oncol.,
January 10, 2009;
27(2):
250 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, P. G. Gobbi, F. Angrilli, M. Brugiatelli, P. Musto, and M. Federico
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study
Haematologica,
September 1, 2008;
93(9):
1335 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sacchi
Reply to: [Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403
Haematologica,
July 1, 2008;
93(7):
e58 - e58.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Bluhm, C. Ronckers, R. J. Hayashi, J. P. Neglia, A. C. Mertens, M. Stovall, A. T. Meadows, P. A. Mitby, J. A. Whitton, S. Hammond, et al.
Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
Blood,
April 15, 2008;
111(8):
4014 - 4021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, S. Luminari, M. Lombardo, G. Buda, A. Lazzaro, P. G. Gobbi, et al.
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study
Haematologica,
March 1, 2008;
93(3):
398 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Haematologica,
October 1, 2007;
92(10):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon, S. Revell, K. Vo, and A. Molina
Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy
J. Clin. Oncol.,
September 20, 2007;
25(27):
4285 - 4292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Sanna, K Lorizzo, N Rotmensz, V Bagnardi, S Cinieri, M Colleoni, F Nole, and A Goldhirsch
Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors
Ann. Onc.,
February 1, 2007;
18(2):
288 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Y. Mudie, A. J. Swerdlow, C. D. Higgins, P. Smith, Z. Qiao, B. W. Hancock, P. J. Hoskin, and D. C. Linch
Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study
J. Clin. Oncol.,
April 1, 2006;
24(10):
1568 - 1574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Moser, E. M. Noordijk, F. E. van Leeuwen, S. le Cessie, J. W. Baars, J. Thomas, P. Carde, J. H. Meerwaldt, M. van Glabbeke, and H. C. Kluin-Nelemans
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Blood,
April 1, 2006;
107(7):
2912 - 2919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Sill, W. Olipitz, and M. G. Schimek
Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia After Autologous Bone Marrow Transplantation: Dosis Facit Venenum?
J. Clin. Oncol.,
November 1, 2005;
23(31):
8120 - 8121.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Brown and A. S. Freedman
In Reply:
J. Clin. Oncol.,
November 1, 2005;
23(31):
8121 - 8122.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin, E. Estey, A. Glassman, J. Romaguera, F. Samaniego, A. Ayala, K. Hayes, A. M. Maddox, H. A. Preti, and F. B. Hagemeister
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
Blood,
June 15, 2005;
105(12):
4573 - 4575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tanvetyanon, M. Adli, A. Sevinc, M. E. Kalender, S. Hoecht, W. Hinkelbein, F. Reyes, and H. Tilly
Treatment of Localized Lymphoma
N. Engl. J. Med.,
June 9, 2005;
352(23):
2449 - 2451.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dranitsaris, M. Johnston, S. Poirier, T. Schueller, D. Milliken, E. Green, and B. Zanke
Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature
Journal of Oncology Pharmacy Practice,
June 1, 2005;
11(2):
69 - 78.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. S.J. Duchateau and M. P.M. Stokkel
Second Primary Tumors Involving Non-small Cell Lung Cancer: Prevalence and Its Influence on Survival
Chest,
April 1, 2005;
127(4):
1152 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Brown, H. Yeckes, J. W. Friedberg, D. Neuberg, H. Kim, L. M. Nadler, and A. S. Freedman
Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 1, 2005;
23(10):
2208 - 2214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Reyes, E. Lepage, G. Ganem, T. J. Molina, P. Brice, B. Coiffier, P. Morel, C. Ferme, A. Bosly, P. Lederlin, et al.
ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma
N. Engl. J. Med.,
March 24, 2005;
352(12):
1197 - 1205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tichelli and G. Socie
Considerations for Adult Cancer Survivors
Hematology,
January 1, 2005;
2005(1):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
